Pfizer have won the battle to acquire American biotech company Medivation in a $14billion deal (£11billion). However, EdenTree’s Ketan Patel tells the Daily Express that the long term question for investors is whether Pfizer has overpaid for Medivation.
As the world transitions to net zero, can oil majors remain investible? Natasha Landell-Mills, head of stewardship at Sarasin & Partners and Joe Mares, portfolio manager of the Trium...
‘What has changed is investors’ interest in the decarbonisation process.’ Trium Capital’s Joe Mares, portfolio manager of the Trium ESG Emissions Impact Fund, discusses company engagement across the evolving...
Is time running out to stop the ‘disturbing’ biodiversity loss currently playing out? Experts from Gresham House, Ecoforests Asset Management, Sarasin & Partners and EdenTree Investment Management, discuss biodiversity...
